Concepts (136)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| HIV Infections | 23 | 2025 | 5097 | 0.980 |
Why?
|
| Anti-HIV Agents | 13 | 2025 | 1324 | 0.880 |
Why?
|
| Sarcoma, Kaposi | 5 | 2024 | 53 | 0.880 |
Why?
|
| Tuberculosis | 6 | 2024 | 543 | 0.630 |
Why?
|
| Isoniazid | 5 | 2024 | 110 | 0.580 |
Why?
|
| Anti-Retroviral Agents | 7 | 2022 | 551 | 0.570 |
Why?
|
| AIDS-Related Opportunistic Infections | 5 | 2024 | 195 | 0.560 |
Why?
|
| Antiretroviral Therapy, Highly Active | 7 | 2020 | 472 | 0.560 |
Why?
|
| Micronutrients | 3 | 2018 | 11 | 0.400 |
Why?
|
| Rifampin | 4 | 2022 | 197 | 0.380 |
Why?
|
| Adult | 21 | 2025 | 5913 | 0.370 |
Why?
|
| C-Reactive Protein | 4 | 2015 | 96 | 0.370 |
Why?
|
| Pre-Exposure Prophylaxis | 2 | 2025 | 196 | 0.370 |
Why?
|
| Antineoplastic Agents, Phytogenic | 3 | 2020 | 10 | 0.360 |
Why?
|
| Inflammation | 4 | 2023 | 104 | 0.340 |
Why?
|
| Female | 21 | 2025 | 9103 | 0.320 |
Why?
|
| Humans | 25 | 2025 | 14537 | 0.310 |
Why?
|
| Male | 19 | 2024 | 6754 | 0.300 |
Why?
|
| Biomarkers | 3 | 2023 | 327 | 0.300 |
Why?
|
| Medication Adherence | 3 | 2025 | 151 | 0.290 |
Why?
|
| Etoposide | 4 | 2023 | 4 | 0.290 |
Why?
|
| Nevirapine | 3 | 2022 | 146 | 0.250 |
Why?
|
| Alkynes | 3 | 2022 | 117 | 0.250 |
Why?
|
| Cyclopropanes | 3 | 2022 | 123 | 0.240 |
Why?
|
| Antitubercular Agents | 4 | 2024 | 322 | 0.240 |
Why?
|
| Malnutrition | 2 | 2017 | 56 | 0.240 |
Why?
|
| Benzoxazines | 3 | 2022 | 123 | 0.240 |
Why?
|
| Patient Preference | 1 | 2025 | 30 | 0.230 |
Why?
|
| Abortion, Spontaneous | 1 | 2024 | 15 | 0.220 |
Why?
|
| Counseling | 1 | 2024 | 143 | 0.210 |
Why?
|
| Tenofovir | 1 | 2024 | 171 | 0.210 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 2 | 2020 | 33 | 0.200 |
Why?
|
| Premature Birth | 1 | 2024 | 80 | 0.200 |
Why?
|
| Young Adult | 7 | 2025 | 2498 | 0.190 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2023 | 187 | 0.190 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2020 | 2 | 0.170 |
Why?
|
| Bleomycin | 1 | 2020 | 2 | 0.170 |
Why?
|
| Coinfection | 2 | 2020 | 276 | 0.170 |
Why?
|
| Vincristine | 1 | 2020 | 5 | 0.170 |
Why?
|
| Viral Load | 3 | 2020 | 819 | 0.160 |
Why?
|
| CD4 Lymphocyte Count | 5 | 2020 | 656 | 0.160 |
Why?
|
| Latent Tuberculosis | 1 | 2019 | 45 | 0.150 |
Why?
|
| Treatment Outcome | 5 | 2020 | 889 | 0.150 |
Why?
|
| Developing Countries | 3 | 2020 | 400 | 0.150 |
Why?
|
| Selenium | 2 | 2015 | 3 | 0.140 |
Why?
|
| Prospective Studies | 5 | 2025 | 1160 | 0.140 |
Why?
|
| Health Resources | 2 | 2018 | 66 | 0.140 |
Why?
|
| Vitamin A Deficiency | 1 | 2017 | 5 | 0.140 |
Why?
|
| Vitamin D | 2 | 2015 | 41 | 0.140 |
Why?
|
| Secondary Prevention | 1 | 2017 | 20 | 0.130 |
Why?
|
| Vitamin D Deficiency | 1 | 2017 | 27 | 0.130 |
Why?
|
| Inflammation Mediators | 1 | 2016 | 22 | 0.130 |
Why?
|
| Weight Loss | 1 | 2016 | 12 | 0.120 |
Why?
|
| Cohort Studies | 4 | 2024 | 967 | 0.120 |
Why?
|
| Sex Factors | 1 | 2016 | 227 | 0.120 |
Why?
|
| Adolescent | 4 | 2025 | 2985 | 0.120 |
Why?
|
| Africa | 3 | 2025 | 376 | 0.120 |
Why?
|
| Middle Aged | 5 | 2024 | 3601 | 0.120 |
Why?
|
| Body Weight | 1 | 2016 | 111 | 0.120 |
Why?
|
| Weight Gain | 1 | 2016 | 77 | 0.120 |
Why?
|
| Chemokine CXCL10 | 1 | 2015 | 3 | 0.120 |
Why?
|
| Lipopolysaccharides | 1 | 2015 | 37 | 0.110 |
Why?
|
| Anemia | 1 | 2015 | 41 | 0.110 |
Why?
|
| Drug Therapy, Combination | 3 | 2020 | 279 | 0.110 |
Why?
|
| Risk Factors | 4 | 2024 | 1475 | 0.100 |
Why?
|
| Treatment Failure | 3 | 2018 | 175 | 0.090 |
Why?
|
| Administration, Oral | 2 | 2025 | 127 | 0.090 |
Why?
|
| Case-Control Studies | 3 | 2018 | 480 | 0.090 |
Why?
|
| HIV-1 | 1 | 2018 | 1260 | 0.080 |
Why?
|
| South America | 2 | 2020 | 27 | 0.080 |
Why?
|
| Africa South of the Sahara | 2 | 2020 | 353 | 0.070 |
Why?
|
| Disease Progression | 2 | 2020 | 154 | 0.070 |
Why?
|
| Hypoalbuminemia | 1 | 2024 | 1 | 0.060 |
Why?
|
| Multivariate Analysis | 2 | 2015 | 171 | 0.060 |
Why?
|
| Pregnancy Trimester, First | 1 | 2024 | 10 | 0.050 |
Why?
|
| Point-of-Care Systems | 1 | 2024 | 91 | 0.050 |
Why?
|
| Logistic Models | 2 | 2015 | 254 | 0.050 |
Why?
|
| Point-of-Care Testing | 1 | 2024 | 71 | 0.050 |
Why?
|
| Chemoradiotherapy | 1 | 2023 | 3 | 0.050 |
Why?
|
| Interleukin-10 | 1 | 2023 | 9 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2023 | 4 | 0.050 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2023 | 11 | 0.050 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2023 | 14 | 0.050 |
Why?
|
| Ligands | 1 | 2023 | 33 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2025 | 435 | 0.050 |
Why?
|
| Aged | 2 | 2021 | 1740 | 0.050 |
Why?
|
| Pregnancy Outcome | 1 | 2024 | 117 | 0.050 |
Why?
|
| Incidence | 2 | 2015 | 685 | 0.050 |
Why?
|
| Prevalence | 2 | 2017 | 1192 | 0.050 |
Why?
|
| HIV | 1 | 2024 | 380 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2021 | 20 | 0.040 |
Why?
|
| Arylamine N-Acetyltransferase | 1 | 2021 | 10 | 0.040 |
Why?
|
| Pharmacogenetics | 1 | 2021 | 31 | 0.040 |
Why?
|
| Paclitaxel | 1 | 2020 | 5 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 33 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2024 | 1479 | 0.040 |
Why?
|
| Piperazines | 1 | 2020 | 82 | 0.040 |
Why?
|
| Oxazines | 1 | 2020 | 81 | 0.040 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2020 | 85 | 0.040 |
Why?
|
| Pyridones | 1 | 2020 | 100 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 156 | 0.040 |
Why?
|
| Trace Elements | 1 | 2018 | 3 | 0.040 |
Why?
|
| RNA, Viral | 1 | 2020 | 303 | 0.040 |
Why?
|
| Biopsy | 1 | 2018 | 38 | 0.040 |
Why?
|
| Pregnancy | 1 | 2024 | 1862 | 0.040 |
Why?
|
| Skin | 1 | 2018 | 38 | 0.040 |
Why?
|
| Proportional Hazards Models | 1 | 2018 | 163 | 0.040 |
Why?
|
| Infant | 1 | 2024 | 2244 | 0.040 |
Why?
|
| Asia | 1 | 2017 | 72 | 0.030 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2017 | 151 | 0.030 |
Why?
|
| Haiti | 1 | 2016 | 1 | 0.030 |
Why?
|
| Peru | 1 | 2016 | 8 | 0.030 |
Why?
|
| Thailand | 1 | 2016 | 26 | 0.030 |
Why?
|
| Brazil | 1 | 2016 | 47 | 0.030 |
Why?
|
| India | 1 | 2016 | 62 | 0.030 |
Why?
|
| Malawi | 1 | 2016 | 87 | 0.030 |
Why?
|
| United States | 1 | 2016 | 132 | 0.030 |
Why?
|
| Zimbabwe | 1 | 2016 | 120 | 0.030 |
Why?
|
| Carotenoids | 1 | 2015 | 2 | 0.030 |
Why?
|
| Vitamin A | 1 | 2015 | 10 | 0.030 |
Why?
|
| Vitamin E | 1 | 2015 | 9 | 0.030 |
Why?
|
| Risk | 1 | 2015 | 87 | 0.030 |
Why?
|
| Atazanavir Sulfate | 1 | 2014 | 10 | 0.030 |
Why?
|
| Pyridines | 1 | 2014 | 11 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2014 | 12 | 0.030 |
Why?
|
| Didanosine | 1 | 2014 | 11 | 0.030 |
Why?
|
| Oligopeptides | 1 | 2014 | 16 | 0.030 |
Why?
|
| Global Health | 1 | 2015 | 193 | 0.030 |
Why?
|
| Zidovudine | 1 | 2014 | 59 | 0.030 |
Why?
|
| Emtricitabine | 1 | 2014 | 78 | 0.030 |
Why?
|
| Lamivudine | 1 | 2014 | 89 | 0.030 |
Why?
|
| World Health Organization | 1 | 2014 | 137 | 0.030 |
Why?
|
| African Americans | 1 | 2014 | 47 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2014 | 133 | 0.030 |
Why?
|
| Body Mass Index | 1 | 2014 | 321 | 0.020 |
Why?
|
| South Africa | 1 | 2016 | 7596 | 0.010 |
Why?
|